Given the association of CDKN2B-AS1 expression and variants with cancer and the limitation of related studies in our region, the current study aimed to (1) investigate the impact of circulating CDKN2B-AS1 expression and the intronic variant rs2383207 A>G (which has not been studied before) on BC risk and prognosis, (2) execute bioinformatics analysis for the specified lncRNA and (3) verify the present results against data in The Cancer Genomic Atlas (TCGA). This evidence concerns the gene CDKN2B and breast cancer.